Revenue
2010
2011
2012
2013
2014
2015
2016
2022
2023
2024
2025
Lisata Therapeutics, Inc. (LSTA)
Price$1.63Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 | — | — | — | — | — | $35.3M | $22.5M | $17.9M | $14.7M | $14.3M | $10.1M | $69.8M |
| Gross profit | — | — | — | — | — | — | — | — | — | $4.1M | $2.3M | $2.3M | $1.7M | $2.4M | $1.4M | $20.2M |
| Gross margin | — | — | — | — | — | — | — | — | — | 11.76% | 10.36% | 12.60% | 11.73% | 16.61% | 13.96% | 28.86% |
| Research & development | $7.9M | $11.3M | $12.7M | $13.1M | $17.6M | $9.3M | $10.8M | $7.6M | $15.8M | $16.7M | $23.9M | $29.2M | $16.9M | $10.5M | $7.7M | $7.7M |
| Operating expenses | $18.4M | $23.4M | $25.7M | $57.6M | $29.1M | $19.1M | $20.1M | $17.0M | $27.6M | $29.5M | $136.3M | $75.7M | $51.5M | $44.7M | $35.4M | $39.0M |
| Operating income | −$18.2M | −$22.4M | −$25.7M | −$57.6M | −$29.1M | −$19.1M | −$20.1M | −$17.0M | −$27.6M | −$29.5M | −$113.8M | −$57.7M | −$36.8M | −$30.4M | −$34.0M | −$18.9M |
| Operating margin | −10,711.18% | −2,240.90% | — | — | — | — | — | — | — | −83.61% | −506.28% | −321.88% | −250.94% | −212.04% | −338.35% | −27.04% |
| EBITDA | −$18.1M | −$22.2M | −$25.5M | −$57.5M | −$29.0M | −$19.0M | −$20.0M | −$16.8M | −$27.2M | −$29.0M | −$111.7M | −$56.1M | −$35.8M | −$29.4M | −$32.6M | −$13.7M |
| EBITDA margin | −10,625.29% | −2,223.50% | — | — | — | — | — | — | — | −82.20% | −496.94% | −312.96% | −244.12% | −205.07% | −324.02% | −19.68% |
| Net income | −$16.6M | −$20.0M | −$20.8M | −$54.2M | −$27.5M | −$8.2M | −$19.4M | −$16.2M | $23.0M | −$32.7M | −$81.0M | −$54.9M | −$39.0M | −$53.8M | −$47.1M | −$23.3M |
| Net profit margin | −9,756.47% | −1,998.50% | — | — | — | — | — | — | — | −92.55% | −360.25% | −305.89% | −265.75% | −375.23% | −469.00% | −33.38% |
| Basic EPSper basic share | -$1.91 | -$2.40 | -$2.58 | -$10.47 | -$7.45 | -$0.99 | -$3.52 | -$3.13 | $4.80 | -$9.35 | -$31.23 | -$31.47 | -$35.59 | -$74.93 | -$101.16 | -$86.17 |
| Diluted EPSper diluted share | -$1.91 | -$2.40 | -$2.58 | -$10.47 | -$7.45 | -$0.99 | -$3.52 | -$3.13 | $4.80 | -$9.35 | -$31.23 | -$31.47 | -$35.59 | -$74.93 | -$101.16 | -$86.17 |
Owners
Reported shareholders
≈3.42%of listed shares
Mazzo David J311.89K shares · Jan 9, 2026
View holders
| Holder | % owned |
|---|---|
Mazzo David J | ≈3.42%311.89K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.06%278.84K shares |
Yakira Capital Management, Inc. | 1.52%138.56K shares |
CSS LLC/IL | 1.21%110.42K shares |
AZAB MOHAMMAD | ≈1.15%104.93K shares |
KLOSK STEVEN M | ≈1.05%95.82K shares |
BROWN GREGORY B | ≈1.05%95.66K shares |
Flowers Cynthia Louise | ≈1.05%95.45K shares |
Buck Kristen K | ≈1.02%93.46K shares |
HENSON HEIDI | ≈0.94%85.73K shares |
DELTEC ASSET MANAGEMENT LLC | 0.91%83.2K shares |
Rangeley Capital, LLC | 0.89%81K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.80%72.63K shares |
Virtu Financial LLC | 0.64%58.78K shares |
BlackRock, Inc. | 0.60%54.86K shares |
VANGUARD FIDUCIARY TRUST CO | 0.54%48.96K shares |
Imam Tariq | ≈0.40%36.08K shares |
Nisco James | ≈0.35%32.31K shares |
GTS SECURITIES LLC | 0.33%30.2K shares |
STATE STREET CORP | 0.28%25.35K shares |
Percentages use 9.12M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Lisata acquires Marea and signs $225 million financing agreement
Lisata ($LSTA) Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction and signed a concurrent agreement for approximately $225 million in gross private-placement proceeds. The financing involves non-voting convertible pre ...
